Introduction:
The patients with antiphospholipid syndrome (APS) associate an increased risk of atherosclerosis.
Objective: To determine the predictors of an abnormal ankle-brachial index (ABI), surrogate measure of atherosclerosis, in patients with APS.
Methods:
The ABI was measured according to standard recommendations in 106 patients. Traditional cardiovascular risk factors were assessed in all cases. A large spectrum of APS antibodies was determined in 73 patients.
Results: A total of 106 patients diagnosed with APS were included. 28.3% patients included were found to have low ABI. Anti-beta 2-glycoprotein I (aβ2GPI) IgG antibodies [4.00 (1.00-79.00) vs 3.00 (0.00-29.00) U/mL, P = 0.02] and antiprothrombin (aPT) IgM antibodies [4.50 (0.00-82.00) vs 3.00 (0.00-14.00) U/mL, P = 0.05] titers were found to be higher in patients with abnormal ABI. However, after multivariate regression analysis, only the aβ2GPI IgG titer remained predictor of low ABI (P = 0.04).
Conclusions: aβ2GPI IgG associated with impaired ABI in patients with APS. This relation might reflect their involvement in the atherosclerosis occurrence.
K E Y W O R D S
ankle-brachial index, antiphospholipid syndrome, beta-2 glycoprotein I, cardiovascular risk (aCL), and anti-β2 glycoprotein I antibodies (aβ2GPI) as well as history of thrombotic or pregnancy events sustaining the APS diagnosis.
The following exclusion criteria were used: active malignancy (solid or hematological), acute or chronic infections, granulomatous chronic diseases, age under 18 years, pregnancy or 6 months postpartum period, and severe chronic renal failure. 
| Statistical analysis
Variables were expressed as mean ± standard deviation and median (min, max) according to their distribution. T-independent, chi-square, and the Mann-Whitney test when appropriate were used to compare two groups. Parameters that proved to be statistically significant in univariate analysis were then tested in a forward conditional multivariate regression model. The cutoff of P probability for rejecting the null hypothesis was 0.05. SPSS 16.0 software (SPSS Inc, Chicago, Illinois, USA) was used for the statistical analysis.
| RE SULTS

| Study cohort
A total of 106 patients with APS were included. The majority was female gender, with a female-to-male ratio of 92:14. The mean ABI value was 0.91 ± 0.18. According to the ABI value, two groups were defined: first group (30 patients) with an ABI value lower than 0.9
General characteristics of the patients as well as the risk factors traditionally associated with atherosclerosis are listed in Table S1 .
When compared to patients with normal ABI, those with low ABI were older both at inclusion (51.1 ± 13.2 vs 42.1 ± 11.1 years, P = 0.001) and at the APS diagnosis (42.9 ± 13.4 vs 36.1 ± 10.6 years, P = 0.07).
In regard to the traditional cardiovascular risk factors, the presence of HTN (63.3% vs 32.9%, P = 0.008) and diabetes (23.3% vs 6.6%, P = 0.02) was significantly higher in patients with low ABI. Also, the values of the pulse pressure (53.8 ± 12.4 vs 48.7 ± 9.8 mm Hg, P = 0.02) and the fasting glucose levels (95.3 ± 17.6 vs 84.6 ± 15.9 mg/ dL, P = 0.004) were higher in the low ABI group.
| Antiphospholipid antibodies
In 73 patients-86% of feminine gender, age at inclusion 44.9 ± 0.18 years, and disease duration 3.0 (1.0-29.0) years-an extended APLA was searched.
For this group of patients, the prevalence of cardiovascular risk factors was as follows: smoking (31.5%), HTN (35.6%), dyslipidemia (53.4%), diabetes (8.2%), and metabolic syndrome (8.2%).
Moreover, the pulse pressure value was 48.7 ± 9.5 mm Hg, waist-hip ratio 0.9 ± 0.1, fasting glucose 88. (Table S2 ).
| Multivariate analysis
In a forward stepwise regression model analyzing parameters associated with ABI in univariate analysis, only the IgG aβ2GPI titer remained predictor of a low ABI (P = 0.04). None of the traditional risk factors of subclinical cardiovascular atherosclerosis analyzed proved to be independent risk factor for impaired ABI in the patients with APS included.
| D ISCUSS I ON
Ankle-brachial index is a useful screening tool for subclinical atherosclerosis and a facile method for the global cardiovascular risk evaluation. 6 Impaired ABI is seven times more frequent in patients with APS than controls, 8 and APLAs presence might be directly involved in the vasculopathy development. 1 In patients with SLE, the occurrence of APS has an additive deleterious effect, determining more aggressive arterial atherosclerosis, especially in young patients. 9 Also, the abnormal low ABI was identified in patients with APS presenting pregnancy pathology and it was hypothesized that a diffuse vascular impairment might contribute to
pregnancy loss in patients with APS. 10 There are also data that did not show any correlation of the abnormal ABI neither with the cardiovascular risk factors nor with the APLAs positivity. 11 To might have final conclusions, there is also the need of standardized testing in APS. 12 Starting from these data, we evaluated the ABI in patients with primary and secondary APS. The group of APS patients with low ABI presented significant higher age, associated HTN and diabetes, higher blood glucose levels, higher pulse pressure values, and lower HDL cholesterol levels in males. Regarding the ten diagnostic and nondiagnostic APLAs tested, we found statistically significant higher titers of aPT IgM and aβ2GPI IgG in patients with low ABI.
However, after multivariate analysis, only the aβ2GPI IgG titer was identified as predictor for an impaired ABI in patients with APS.
The aβ2GPI IgG is diagnostic criteria antibodies, 13 have pathogenic role in APS, 14 and proved good discriminating accuracy for the APS diagnosis. 15 The interaction between the oxidized low-density lipoprotein (ox-LDL), β2GPI, and aβ2GPI is proposed as pathogenic mechanism for atherogenesis development. Ox-LDL, an important component of the atherosclerotic lesions, 16 is localized in the atherosclerotic plaque in the proximity of β2GPI and lymphocytes. 17 The β2GPI probably has antiatherogenic properties, and so the aβ2GPI
antibodies might have proatherogenic effects after inclusion in complexes with ox-LDL and β2GPI. 18 However, there are other conflicting data showing that the APLAs have no relation with atherosclerotic plaques, 19 but only with the APS thrombotic phenomenon. 20 The present research has several limitations. It is a cross-sectional study without prospective follow-up of the patients included. The LAC was not determinate as all determinations were carried out on conserved serum. Nevertheless, a large number of APLAs were tested, ten criteria and noncriteria APS antibodies.
In conclusion, we found a high prevalence of an abnormal ABI
in the patients with APS tested. The aβ2GPI IgG titer was independently associated with impaired ABI, possibly reflecting the role of disease itself in the vasculopathy pathogenesis.
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